GeoVax Labs, Inc. (Nasdaq: GOVX) today underscored the strategic positioning of its oncology asset, Gedeptin (Ad/PNP), as the biopharmaceutical industry increasingly invests in next-generation in vivo cancer therapies. Recent high-profile transactions reflect a growing focus on therapies that simplify delivery, improve scalability, and expand therapeutic reach. However, a central challenge remains: many tumors are immunologically “cold,” limiting the effectiveness of even the most advanced modalities. GeoVax believes Gedeptin is uniquely positioned to address this hurdle.
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally. It is designed to generate purine nucleoside phosphorylase (PNP), which selectively destroys both proliferating and non-proliferating tumor cells within the treated tumor. Preclinical experiments have shown PNP treatment to be additive or synergistic with checkpoint blockade agents. Studies in metastatic tumor models demonstrated that treating a single lesion can sensitize tumors to checkpoint inhibitors, presumably by destroying tumor tissue, exposing neoantigens, and enhancing immune response at distant untreated lesions. This dual mechanism—localized cytotoxicity combined with immune sensitization—has the potential to improve therapeutic approaches to solid tumor metastatic disease.
“While the industry is investing heavily in next-generation cell and gene therapies, the ability to positively modify the local tumor environment is believed to be one of the critical determinants of clinical success,” said David A. Dodd, Chairman and CEO of GeoVax. “Gedeptin is designed to directly destroy both proliferating and non-proliferating tumors, while also demonstrating high bystander activity due to the ability of the in situ generated cytotoxic agent to diffuse into neighboring tumor cells.”
GeoVax has generated preclinical, clinical, and translational data supporting Gedeptin’s ability to induce localized tumor cell death while minimizing systemic toxicity and potentially improve response rates when combined with immune checkpoint inhibitors. As checkpoint inhibitors move earlier in treatment paradigms, including neoadjuvant and first-line settings, the need for complementary approaches that enhance response rates is becoming increasingly evident. GeoVax is advancing Gedeptin in combination with checkpoint inhibition in a planned Phase 2 clinical trial for first-line head and neck cancer, with additional solid tumor indications under evaluation.
“Checkpoint inhibitors have transformed cancer care, but many patients still do not achieve durable responses,” said Kelly T. McKee, M.D., Chief Medical Officer of GeoVax. “We believe Gedeptin is well positioned as a combination-enabling platform designed to enhance therapeutic response across checkpoint inhibitors and other emerging oncology modalities.” Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers. The company continues to evaluate strategic partnerships to advance clinical development and potential commercialization.
